Marksans Pharma's UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
By Aditya Bhagchandani Published on June 19, 2025, 09:14 IST
Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA).
The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans' offering in the urology therapeutic segment and strengthens its European portfolio.
The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia's TGA.
'This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,' the company said in a press release.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
12 minutes ago
- Forbes
Low Concentrations Of Air Pollution Can Still Impact Health, Study Finds
HOBOKEN, NJ - JULY 20: The sun rises on the skyline of lower Manhattan and One World Trade Center in ... More New York City as a man walks through a park on July 20, 2023, in Hoboken, New Jersey. (Photo by) Exposure to air pollution air even at low concentrations can still have significant air impacts, according to a new analysis. The report by the Royal College of Physicians (RCP) highlights the growing evidence about the health impacts linked to air pollution and calls on the U.K. government to treat it as a serious and preventable health risk. It emphasises that poor ventilation, damp and mould, and emissions from domestic heating, gas cooking and household products all contribute significantly to poor health. The study, which has been published to mark Clean Air Day (19 June), also warns air pollution could contribute towards 30,000 deaths in the U.K. this year and cost the NHS and the economy billions. It urges the U.K. government to recognise air pollution as a public health issue, rather than a solely environmental one and tackle emissions from various sources, including wood burning, agriculture, transport and indoor pollutants. And it also calls for targeted support to protect the most vulnerable and affected communities and a nationwide public health campaign on air pollution. The RCP's special adviser on air quality, Professor Sir Stephen Holgate, from the University of Southampton, said up to 700 diseases have now been linked with air pollution in an interview. Professor Holgate added air pollution itself has changed and there is growing evidence to show how smaller pollution particles can penetrate the lungs and enter the bloodstream. 'Air quality is also interacting with many other factors,' he told me. 'It only very rarely causes a single disease, but can interact with other health issues, like diet, lifestyle, inequalities, and stress to act like a catalyst and force them to accelerate disease processes than in the absence of pollution.' Professor Holgate added air pollution is traditionally regarded as an environmental issue, but now needs to be seen much more as a public health concern. 'We need to get more public health messaging out there, and better champions in local authorities, GP surgeries and hospitals to tell the story about why air pollution is bad for you, and what can be done about it. 'And we have got to integrate air pollution policies with climate change policies, because some of these air pollutants like black carbon, are up to 1,500 times more potent than carbon dioxide at global warming and therefore cleaning up our urban environment will have a big impact towards achieving net zero,' he added. Clean Air Day is a national event organised by the non-profit Global Action Plan. As part of this year's event, more than 100 healthcare professionals will meet today at Great Ormond Street Hospital for Children (GOSH) in London and march to Parliament Square to demand action on air pollution. When they arrive, they will deliver a letter to the U.K government, which calls on it to meet World Health Organization (WHO) air quality guidelines. Global Action Plan's director of policy and campaigns, Larissa Lockwood said air pollution levels in urban areas across the country currently exceed the recommended limits set by the WHO, in a statement. This Clean Air Day healthcare workers and organisations have sent a clear message to the U.K. government that it's time to bring our air quality targets in line with the overwhelming medical consensus,' added Lockwood. The charity Asthma + Lung UK has also released the details of a new poll for Clean Air Day, which highlights the impact air pollution can have on people's health. Almost one in five of people with lung conditions surveyed said air pollution had caused an asthma attack or serious flare-up, while more than half said it left them feeling breathless. The poll also found nearly one in six respondents said they avoid leaving home when air pollution levels are high, and one in 10 reported feeling low or depressed because of it. Even among those who believe they're not affected by air pollution, a third of those surveyed were unaware of the risks, suggesting a significant gap in awareness.5 Asthma + Lung UK chief executive Sarah Sleet said the U.K. urgently needs tougher air quality laws, aligned with WHO guidelines, in a statement.
Yahoo
17 minutes ago
- Yahoo
Whitbread sales under pressure amid overhaul and tough UK market
Premier Inn owner Whitbread has posted falling sales amid a 'challenging' UK market and a major restaurant overhaul. The group, which also owns the Beefeater and Brewers Fayre chains, reported a 2% drop in total accommodation sales across the UK in its first quarter to May 29, with food sales plunging by 16% as it revamped its restaurants business. Food and drink sales have been impacted by a restructure that Whitbread started in April last year, which includes cutting back its restaurant business to build more hotel rooms. The £500 million plan, which executives dubbed 'Accelerating Growth', involves converting 112 branded restaurants into new hotel rooms and selling 126 more. The plans announced in April 2024 will also see around 1,500 jobs axed as it looks to save about £150 million over the next three years. Whitbread said on Thursday it was on track to save £60 million in this financial year. On a like-for-like basis, it said first-quarter accommodation sales fell 3% and food-and-drink sales dropped 2%. But it enjoyed a more robust performance in Germany, with total accommodation sales up 15% and food up 22%. Dominic Paul, Whitbread chief executive, said: 'We continue to execute our strategic priorities at pace and are making excellent progress with our Accelerating Growth plan and network expansion in both the UK and Germany. 'In the UK, we continue to outperform against a challenging market backdrop. 'Our forward booked position remains ahead of last year and whilst forward visibility remains limited, our commercial initiatives are underpinning our confidence in being able to continue to outperform the market.'
Medscape
36 minutes ago
- Medscape
GLP-1 Use in Europe Hampered by Stigma and Cost
AMSTERDAM — At the HLTH Europe 2025 conference, experts discussed the nuanced landscape of GLP-1 medications in Europe, revealing a complex interplay of skepticism, financial hurdles, and evolving perceptions of obesity. While clinical evidence supporting GLP-1s is growing, European healthcare providers have not widely adopted these medications, particularly in the public sector. Manuel Nothelfer According to Manuel Nothelfer, co-founder and CEO of Wellster, stringent regulations, societal stigma that still often views obesity as a 'lifestyle choice' rather than a disease, and the financial burden on public health systems lead to a tendency to view GLP-1s as a 'last resort' treatment. This is why there is less uptake in Europe than in the US. Tessy Huss, director of strategy at HLTH community, added that some European countries have yet to formally classify obesity as a disease — a factor that limits access to treatment. In the UK, where 28% of the population has obesity, the National Health Service feels primary care isn't equipped to handle widespread GLP-1 medication distribution, explained Ro Huntriss, a registered dietitian and the chief nutrition officer at Simple App. Tessy Huss There is a need for more staffing, greater healthcare professional education, and the integration of digital health solutions, she said. It is also important to ensure a consistent medication supply to prevent interrupting patient treatment plans. 'There is not an acceptable patient journey,' she added. Beyond BMI: Redefining Eligibility and Benefits As scientists continue to learn how GLP-1 medications work, it is becoming clear that the benefits go beyond mere weight loss. Studies have observed a significant reduction in cardiovascular events, an impact on inflammatory processes, and even improvements in sleep apnea and neurodegenerative diseases, according to Ihsan Almarzooqi, MD, co-founder of These findings are prompting a reevaluation of eligibility criteria beyond BMI. 'BMI alone might not be the best measure,' said Scott Honken, chief commercial officer at WeightWatchers, suggesting that a more holistic approach incorporating metabolic syndrome diagnosis would provide a 'much better picture for whom should be taking these medications.' This expanded understanding of GLP-1 benefits also contributes to the ongoing debate about their high upfront costs. While the direct cost of GLP-1s can be substantial, the broader health improvements and reduced need for other medical interventions could lead to significant long-term savings. 'The curve is starting to bend around 2 or 3 years,' said Honken; that is the point at which the return on investment becomes positive due to reduced emergency room visits and other medical cost savings. A Lifestyle Change Is Not Negotiable Ro Huntriss However, despite these broader benefits and evolving economic arguments, the panel stressed that lifestyle interventions are nonnegotiable in obesity management. GLP-1s are a powerful tool, but they are not a standalone solution, said Huntriss. 'Good diet and lifestyle can reduce blood pressure, it can reduce cholesterol, it can improve inflammation. We shouldn't just go straight to the medication.' She added that a critical missing element in current treatment paradigms is comprehensive, ongoing support, with a multidisciplinary approach that includes dietitians, exercise practitioners, and coaches. 'If people don't have that wrap-around support, they are less likely to adhere to treatment and achieve sustainable outcomes,' she said. Patients need to understand that GLP-1s are part of a broader behavioral change strategy. Simply taking the medication without addressing lifestyle factors often leads to weight regain once the drug is stopped, Honken said. Moreover, even with weight loss from GLP-1s, patients need guidance to ensure they remain well-nourished, Huntriss said. Huss reported having no relevant financial relationships.
